Moss, 7 November 2019
Gentian Diagnostics AS announces its results for the third quarter of 2019.
The highlights include:
- Record sales revenues of MNOK 13.1 in 3Q19, up from MNOK 10.4 in 3Q18, totaling a 26 % growth YOY
- Record sales revenue for the first nine months of MNOK 33.9 representing 18% growth compared to the same period of 2018
- In July, Gentian and Beckman Coulter, one of the top 5 global diagnostics companies, prolongated their partnership agreement for Cystatin C by 6 years
- In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG
Please find the report and results presentation here:
7th Nov 2019 - Quarterly Report - Q3
7th Nov 2019 - Quarterly Presentation - Q3
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 488795
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL